Literature DB >> 10216793

Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment.

R van Reekum1, M Simard, K Farcnik.   

Abstract

OBJECTIVE: To highlight the importance of family physicians in the management of Alzheimer's disease (AD) and related dementias. To provide an update on the diagnostic workup of people with suspected dementia and on the pharmacologic management of cognitive impairment and disease progression in AD. QUALITY OF EVIDENCE: MEDLINE and Psychological Abstracts were searched using the terms "cognitive enhancers" or a specific drug name and "dementia (exp)." Evidence is generally limited but promising. Methodologic flaws in existing research likely to affect clinicians are briefly reviewed. MAIN MESSAGE: Increasing evidence suggests that early intervention can delay the progression of AD and improve the symptoms and function of those affected. Available treatments have modest but important effects on the outcome of patients with AD; some patients respond dramatically. Most currently available treatments are relatively safe in carefully selected cases.
CONCLUSIONS: The diagnostic workup of most cases of dementia can at least be initiated in family physicians' offices. Beginning the workup is important because, for treating AD, the earlier you start, the better. Donepezil, vitamin E, and, in the near future, propentofylline are the main pharmacologic choices for improving cognition and slowing disease progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216793      PMCID: PMC2328342     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  43 in total

Review 1.  Cognition-enhancing drugs in dementia: a guide to the near future.

Authors:  R van Reekum; S E Black; D Conn; D Clarke
Journal:  Can J Psychiatry       Date:  1997-06       Impact factor: 4.356

2.  A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.

Authors:  P L Le Bars; M M Katz; N Berman; T M Itil; A M Freedman; A F Schatzberg
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

Review 3.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 4.  From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia.

Authors:  N Herrmann; K L Lanctôt
Journal:  Can J Psychiatry       Date:  1997-06       Impact factor: 4.356

5.  A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations.

Authors:  B L Miller; C Ikonte; M Ponton; M Levy; K Boone; A Darby; N Berman; I Mena; J L Cummings
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

6.  A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.

Authors:  J Marcusson; M Rother; B Kittner; M Rössner; R J Smith; T Babic; V Folnegovic-Smalc; H J Möller; K H Labs
Journal:  Dement Geriatr Cogn Disord       Date:  1997 Sep-Oct       Impact factor: 2.959

7.  Patterns of neuropsychological impairment in mild dementia: a comparison between Alzheimer's disease and multi-infarct dementia.

Authors:  A Padovani; V Di Piero; M Bragoni; M Iacoboni; G F Gualdi; G L Lenzi
Journal:  Acta Neurol Scand       Date:  1995-12       Impact factor: 3.209

8.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

Authors:  S L Rogers; L T Friedhoff
Journal:  Dementia       Date:  1996 Nov-Dec

9.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 10.  Fronto-temporal dementia: nosology, neuropsychology, and neuropathology.

Authors:  D Neary; J Snowden
Journal:  Brain Cogn       Date:  1996-07       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.